Autolus Therapeutics reports Q2 AUCATZYL revenue of $20.9mln, on track for LN, MS trials.

• Autolus Therapeutics reports Q2 2025 AUCATZYL net revenue of $20.9 million • AUCATZYL received conditional marketing authorization from the MHRA and EC • Obe-cel's long-term remission potential in r/r B-ALL demonstrated in FELIX trial data • Phase 2 pivotal trial in LN and Phase 1 trial in progressive MS to initiate by year-end 2025 • Autolus Therapeutics to host a conference call today at 08:30 am EDT/13:30 pm BST

Autolus Therapeutics plc (Nasdaq: AUTL) has announced its operational and financial results for the second quarter ended June 30, 2025. The company reported net product revenue of $20.9 million for the quarter, with a total of $29.9 million for the first six months of 2025. The company also received conditional marketing authorization for AUCATZYL from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the European Commission (EC) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).

The FELIX trial, which presented data at the 2025 European Hematology Association (EHA) Congress, demonstrated obe-cel's potential for long-term remission in r/r B-ALL. The updated median duration of response (mDOR) is now 42.5 months, and 38.4% of responders are in ongoing remission without consolidative stem cell therapy or other therapies at the updated median follow-up of 32.8 months. The 24-month probability of Event Free Survival was 43%, and the Overall Survival was 46%, with a further consolidating long-term plateau observed.

Autolus is also on track to initiate a Phase 2 pivotal clinical trial in lupus nephritis (LN) and a Phase 1 clinical trial in progressive forms of multiple sclerosis (MS) by year-end 2025. The company has aligned with the U.S. Food and Drug Administration (FDA) on the Phase 2 trial design and potential registrational path to approval for LN. The company continues to anticipate dosing the first patient in a Phase 1 dose escalation study in progressive MS by year-end 2025.

The company's financial results for the quarter include net product sales of $20.9 million, cost of sales of $24.4 million, research and development expenses of $27.4 million, selling, general and administrative expenses of $30.3 million, and a loss from operations of $61.2 million. The company ended the quarter with cash, cash equivalents and marketable securities of $454.3 million.

Autolus Therapeutics will host a conference call today at 08:30 am EDT/13:30 pm BST to discuss these results and business updates. Investors are encouraged to pre-register for the call using the link at the bottom of the press release.

References:
[1] https://www.globenewswire.com/news-release/2025/08/12/3131530/0/en/Autolus-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Business-Updates.html